Dosage, usage and individualized medication recommendations of pirfenidone (Asri)

Pirfenidone (Pirfenidone, trade name: Esbriet) is an oral anti-fibrotic drug mainly used to treat idiopathic pulmonary fibrosis (IPF). The standard recommended dose is 2403mg, taken orally in three divided doses, approximately 801mg each time. It needs to be taken with meals to reduce gastrointestinal discomfort. Doses are usually titrated starting at a low dose to improve tolerability, and are usually titrated to the full dose over 2 weeks.

Patients may experience gastrointestinal reactions (such as nausea, diarrhea), rash, or liver function abnormalities while taking the drug. According to the tolerance of different patients, the dose can be appropriately adjusted or the escalation cycle can be extended. For example, for elderly patients or those with mildly impaired liver and kidney function, doctors may consider extending the dose escalation time or temporarily reducing the dose when symptoms become apparent to ensure the safety of the treatment.

Pirfenidone should be taken with food and avoid taking it on an empty stomach to reduce gastrointestinal irritation. In order to maintain a stable drug concentration in the body, it is recommended that patients take the drug at a fixed time and try to take the drug continuously without skipping a dose or increasing the dosage on your own. If you accidentally miss a dose, you can take it as soon as possible on the same day. However, if it is close to the next dose time, you should skip the missed dose and continue taking the medicine as originally planned.

During treatment, patients should regularly monitor liver function and blood routine, and pay attention to skin reactions and photosensitivity. Avoid prolonged direct sunlight and use sun protection to reduce the risk of photosensitivity reactions. For patients with other medical conditions or long-term use of other drugs, their doctors should be informed to avoid drug interactions. Through individualized dose adjustment and standardized medication management, most patients can safely tolerate pirfenidone and obtain long-term anti-fibrotic effects.

Reference materials:https://www.drugs.com/